Clinical trial
A Multicenter Expanded Access Treatment Protocol of Lurbinectedin (PM01183) in Previously Treated Small Cell Lung Cancer in the USA
NCT04291937 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Expanded Access Treatment Protocol of Lurbinectedin (PM01183) in Previously Treated Small Cell Lung Cancer in the USA
- Lead sponsor
- Jazz Pharmaceuticals
- Phase
- Expanded access
- Overall status
- Approved for marketing
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
small cell lung cancer